Published in final edited form as:

Genes Immun. 2010 March ; 11(2): 99–112. doi:10.1038/gene.2009.83.

Regulation of MHC class II gene expression, genetic variation and disease

Lahiru Handunnetthi, MSc^{1,2}, Sreeram V. Ramagopalan, DPhil^{1,2}, George C. Ebers, MD^{1,2}, and Julian C. Knight, DPhil^{1,*}

¹Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK

²Department of Clinical Neurology, University of Oxford, Oxford OX3 7BN, UK

Abstract

Major histocompatibility complex (MHC) class II molecules are central to adaptive immune responses and maintenance of self-tolerance. Since the early 1970s the MHC class II region at chromosome 6p21 has been shown to be associated with a remarkable number of autoimmune, inflammatory and infectious diseases. Given that a full explanation for most MHC class II disease associations has not been reached through analysis of structural variation alone, in this review we explore the role of genetic variation in modulating gene expression. We describe the intricate architecture of the MHC class II regulatory system, indicating how its unique characteristics may relate to observed associations with disease. There is evidence that haplotype-specific variation involving proximal promoter sequences can alter the level of gene expression, potentially modifying the emergence and expression of key phenotypic traits. Although much emphasis has been placed on *cis*-regulatory elements, we also explore the role of more distant enhancer elements together with the evidence of dynamic inter- and intra-chromosomal interactions and epigenetic processes. The role of genetic variation in such mechanisms may hold profound implications for susceptibility to common disease.

Keywords

MHC; HLA; transcription; gene regulation; polymorphism; autoimmune

Introduction

Major histocompatibility complex (MHC) class II molecules are cell-surface glycoproteins that play a central role in the immune system by presenting peptides to the antigen receptor of CD4⁺ T cells.¹ Antigen presentation is not only crucial for the regulation of protective immune responses against invading pathogens, but is also necessary for the maintenance of self-tolerance. Indeed, MHC class II expression directs positive and negative selection processes that shape the specificity of the T-cell-receptor repertoire of the CD4⁺ T-cell population during its development in the thymus.²

It is therefore perhaps not surprising to find that the human MHC class II gene region holds the largest number, and some of the longest recognised, associations with autoimmune diseases of any similar-sized region across the genome (Table 1). Early associations based on serological typing were established for multiple sclerosis^{3,4}, type I diabetes^{5,6} and

* to whom correspondence should be addressed. Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Headington Oxford OX3 7BN, UK Tel. +44 (0)1865 287651; fax +44 (0)1865 287533; julian@well.ox.ac.uk.

Conflict of interest. The authors declare no conflict of interest.

coeliac disease^{7,8} which were subsequently resolved to specific *HLA-DR/DQ* haplotypes^{9,10} while recent genome-wide association studies using common SNP markers have served to underline the remarkable contribution of this region in susceptibility to autoimmune disease¹¹ which dwarfs any other genetic effect. Although the functional basis for the observed class II associations in autoimmune disease remain incompletely understood, one long held view suggests a breakdown in immunological tolerance to self-antigens through presentation of peptides to auto reactive T cells.¹²

From a genetics standpoint, it has been difficult to clearly determine the disease-causing variant(s) for most MHC class II associated diseases owing to extended linkage disequilibrium and the great sequence diversity exhibited by genes in this region.^{13,15} However, it is becoming increasingly clear that structural variation alone cannot fully account for disease associations in the MHC class II region and there is increasing interest in defining genetic variants which may modulate gene expression.^{16,18} Support for this comes from recent genome-wide analyses of gene expression as a quantitative trait which have highlighted the impact of *cis*-acting genetic variation on expression of class II genes such as *HLA-DQA1*, *HLA-DRB1*, *HLA-DPA1* and *HLA-DQB1*.¹⁸ The observed variation in class II gene expression makes it possible that association of MHC class II polymorphism with disease may relate to the level of gene expression as much or in addition to the restriction of response to antigen.

MHC class II genes and their expression

The human MHC class II cluster includes three classical class II genes (*HLA-DP*, *-DQ*, *-DR*) and two 'non-classical' class II genes (*HLA-DM* and *-DO*) (Figure 1).¹⁹ Some genes are duplicated, one copy of each being functional in the case of *DP* and *DQ*. Depending on the individual, 19 genes may be found in the 0.9Mb of sequence spanned by the class II region including 8 pseudogenes. The antigen presenting molecules comprising α and β chains encoded by the classical class II genes exist as dimers on the cell surface.²⁰ On the other hand, non-classical class II genes are not expressed on the cell surface, but form heterotetrameric complexes and enable peptide exchange and loading onto classical class II molecules.²¹ The class II region includes other functionally clustered genes involved in antigen processing including *TAP1* and *TAP2* (encoding the transporter associated with antigen processing protein), *PSMB8* and *PSMB9* (involved in ubiquitin tagged protein degradation) and, in the extended class II region, *TAPBP*, encoding the TAP binding protein.

Expression of class II genes is tightly regulated, consistent with their critical role in immunity during development and after birth. Their expression is cell-type specific and mainly restricted to thymic epithelial cells (TECs) and bone marrow derived antigen presenting cells (APCs) which include B cells, macrophages and dendritic cells.^{22,23} Levels of class II expression also vary according to the developmental stage of APCs. For example, differentiation of B cells into plasma cells as well as maturation of dendritic cells is characterised by the repression of MHC class II gene expression. Moreover, activated T cells are known to express MHC class II molecules²⁴ and recent studies provide evidence for a functionally distinct subset of T regulatory cells as defined by HLA-DR expression.²⁵ Other cell types such as fibroblasts, epithelial and endothelial cells do not express MHC class II molecules unless they are exposed to specific stimuli, notably interferon-gamma (IFN- γ). Levels of class II gene expression also vary in APCs dependent on particular stimuli. MHC class II gene expression may become markedly down regulated in particular physiological or disease states, for example during severe or prolonged infection^{26,28} or B cell lymphoma²⁹ where it is associated with poor outcome.

Regulation of MHC class II gene expression

Expression of MHC class II molecules is regulated primarily at the level of transcription by a complex process involving highly conserved sequences located in the proximal promoter regions upstream of all classical and non-classical MHC class II genes which recruit specific binding factors, generating the MHC class II enhanceosome.^{23,30,33} At the DNA level this regulatory unit comprises four sequences (S, X, X2 and Y boxes) (Figure 2), the 'SXY module', which is found at all MHC class II genes and highly conserved across vertebrates.

The main trans-acting factors that interact with the SXY module were identified by elegant studies delineating genes involved in loss of MHC class II expression in specific B cell lines and patients with Bare Lymphocyte Syndrome (BLS) (OMIM #209920).^{31,34} BLS is a severe hereditary immunodeficiency disease in which there is defective synthesis of class II molecules. Mutations were found in particular groups of BLS patients involving specific genes encoding the proteins binding the SXY module sequences; these included Regulatory Factor X5 (RFX5)³⁵, RFX-associated protein (RFXAP)³⁶ and RFX-associated ankyrin-containing protein (RFXANK) (also known as RFXB).³⁷ Most significant however was the discovery of the remarkable class II transactivator (CIITA), found to be defective in a specific group of BLS patients and cloned using a cell line showing defective class II expression.³⁸

The cytoplasmic association of RFX5 and RFXAP results in a conformational change in RFXAP such that on nuclear translocation it shows a high affinity interaction with RFXANK.³⁹ Together RFX5, RFXAP and RFXANK form the trimeric RFX complex which binds to the X box of the SXY module³⁶ while the X2 and Y boxes are bound by cyclic AMP responsive element binding protein (CREB),⁴⁰ and nuclear transcription factor Y (NF-Y)⁴¹ respectively (Figure 2). This complex set of protein-DNA and protein-protein interactions generates the MHC enhanceosome which is crucial for protecting class II promoters against DNA methylation⁴² and recruitment of CIITA. CIITA acts as an inducible coactivator (dubbed the 'master controller') to regulate transcription of MHC class II gene expression at several different levels including chromatin modifications, transcriptional initiation and elongation, in a cell-type-specific manner (reviewed in ^{23,43}). Although the function of the S box is modified by an unidentified factor, CIITA recruitment is highly dependent on the integrity of the S-box and the precise spacing between S and X boxes.⁴⁴

Expression of the *CIITA* gene (also known as *MHC2TA*) is inducible and found to be tightly linked to coordinated MHC class II expression. The regulation of *CIITA* is highly complex involving four different promoters in a cell and stimulus specific manner.⁴⁵ The *CIITA* gene is located at chromosome 16p13, flanking a region strongly implicated in type 1 diabetes in genome-wide association studies.^{46,47} A number of autoimmune diseases including rheumatoid arthritis and multiple sclerosis were reported to be associated with a specific promoter SNP of *CIITA*⁴⁸ suggesting a general reduction in class II expression may be a risk factor in autoimmune diseases. However the initial disease associations were modest and subsequent studies have been conflicting.^{49,53}

SXY like sequences and MHC class II gene regulation

Although the concept of CIITA regulated transcription of MHC class II genes is well established there is evidence of additional layers of complexity in the control of MHC class II gene expression. The proximal promoter SXY module alone is not sufficient to direct the normal pattern of MHC class II gene expression. For example, *H2-Ea* (*H2-Ea* is a mouse gene encoding histocompatibility 2, class II antigen E alpha) in B-cells of transgenic mice require both the proximal promoter sequences and a distal region located at a considerable distance away from the gene.^{54,55} Deletion of this distal locus control region results in a

profound reduction of *H2-Ea* expression in B cells while thymic expression remains at a normal level indicating a role for *cis*-variation in tissue specific gene expression.⁵⁶

Remarkably, sequence analysis of the distal locus control region revealed an inverted copy of the SXY module ~1.4 kb upstream of the transcriptional start site.⁵⁴ A similar SXY motif was found ~2.3 kb upstream of the orthologous human *HLA-DRA* gene⁵⁷ and shown to bind RFX and CIITA leading to induction of long-range histone acetylation, recruitment of RNA polymerase II and production of low levels of intergenic transcripts.⁵⁸ Several other distal SXY modules acting as transcriptional enhancers have been identified in the MHC class II region.⁵⁹ These distal SXY modules add another tier of complexity to class II gene regulation through long distance control of expression. The notion that they have a tissue specific role is intriguing and it will be of interest to investigate if genetic variation in these distal elements can contribute to disease via cell-type specific MHC class II expression defects.

These findings were further extended using a bioinformatics approach to identify X box-like (XL) sequences not associated with proximal promoters in the class II region. Several XL sequences identified between *HLA-DRA* and *HLA-DRB3* were found to be functionally important based on their ability to bind RFX and CIITA *in vivo*, and drive expression of a reporter gene.⁶⁰ Furthermore, Gomez and colleagues identified a structural interaction between an upstream XL-sequence and the *HLA-DRA* promoter using a chromatin-looping assay.⁶⁰ Strikingly, it appears that certain XL sequences can contribute to a global increase in chromatin accessibility of the class II region and interact with proximal promoter regulatory sequences through DNA looping. This illustrates the involvement of these XL sequences in a complex three dimensional system of gene expression and we will return to this topic in a later section.

MHC haplotypes, sequence variation and class II regulation

The MHC class II region is extraordinarily polymorphic. There are for example more than 400 different *HLA-DRB1* alleles, many of which are relatively recent in origin and human specific.⁶¹ Analysis of *DRB* loci in this region has defined five major haplogroups in which variable numbers of functional genes and pseudogenes are present (Figure 3).^{62,63} The high level of nucleotide diversity in the class II region is likely to reflect balancing selection acting not only on the epitope binding sites⁶⁴ but also on the promoter regions.^{65,66}

Selection involving such non-coding DNA sequences important to gene regulation is supported by the evidence of haplotype-specific variation in MHC class II gene expression. A number of studies carried out in the early 1990s have highlighted the presence of sequence variation in the proximal promoter regions of MHC class II genes, in particular involving the conserved elements important to regulation such as the S, X, X2 and Y box motifs described previously.

Such work was notable for the *HLA-DRB* genes where sequence variation involving conserved proximal promoter elements^{67,70} was associated allelic differences in recruitment of specific binding factors.⁷¹⁻⁷³ Polymorphism altered gene expression in resting cells^{71,74} but interestingly following cytokine activation, variation in the Y rather than the X1 box was significant.⁷⁵ For *HLA-DRB1*, low and high expressing alleles were defined based on reporter gene analysis using specific promoter constructs^{72,73,76-78} and assays of transcript abundance in immortalised B cell lines or B cells from peripheral blood,^{77,79,80} although analysis of nascent and steady state mRNA using the latter did also indicate a role for post-transcriptional mechanisms in some of the differences observed.⁸¹ There was however consistency seen between the *in vitro* reporter assays and assayed transcript levels *in vivo* with higher transcript abundance in resting peripheral B cells with the *DR52* haplogroup

(*HLA-DRB1**03, *11, *13 and *14) as compared to the *DR53* haplogroup (*HLA-DRB1**04, *01 and *09).^{79, 80}

The evidence from *H-2* genes in the mouse supports haplotype-specific differential gene expression with striking evidence of specific promoter variants, for example in the X2 box, resulting in allele-specific expression. Remarkably, this was specific to particular cell types, in macrophages for example altering the subsequent T cell cytokine response.^{82, 83} In humans, quantitative differences in levels of *DRB1* and *DRB3* expression are also highly significant in determining the CD4+ T cell response.^{84, 85}

An analysis illustrating the occurrence of sequence diversity in conserved SXY module motifs for the *HLA-DRB1* promoter is shown in Figure 4. We analysed sequence conservation for different haplotypes and confirmed the presence of haplotype-specific variation in the consensus regulatory sequences which may modulate promoter strength and allele-specific differences in transcriptional activity. Our comparative analysis of these regulatory sequences indicates that the lower expressing *DR53* haplogroup may be an evolutionary distinct branch and harbours a higher degree of variation compared to the other haplogroups.

Allele specific differences in expression have also been defined for other MHC class II genes notably *HLA-DRA* and *HLA-DQB* with variants defined involving proximal promoter elements X, X1 and Y which modulate transcription. As well as altering DNA binding sites for specific regulatory factors such as RFX⁸⁶, sequence differences affecting the spacing of particular motifs were also seen to be highly significant, for example a TG insertion/deletion polymorphism (rs5875386) between the S and X1 boxes in the *HLA-DRBQ1* promoter. This was associated with differences in reporter gene activity and allele-specific expression at the transcript level, *HLA-DQB1**0301 (TG absent) for example being expressed at significantly higher levels than *0302 (TG present).⁸⁷ Analysis of relative allelic expression in cells heterozygous for different class II alleles has been a powerful complimentary approach, helping to resolve differentially expressed alleles such as *HLA-DQB1**0301.^{88, 91} Such studies also highlighted evidence of stimulus and cell type specificity in the effects of sequence variation involving proximal promoter elements, notably the X box.

Further comprehensive studies are needed using the wealth of resequencing data now available and techniques such as chromatin immunoprecipitation to resolve specific functional regulatory variants *in vivo* based detailed mechanistic studies of haplotype-specific protein-DNA interactions and allele-specific expression. The evidence already available however of differences in transcript abundance among class II alleles, and the role of variation in key regulatory motifs, provides important evidence for the presence of functional regulatory variants. This complements more recent data from genome-wide expression quantitative trait mapping which highlighted *cis*-acting markers involving MHC class II genes such as *HLA-DRB1* and confirmed that expression differences were heritable.¹⁸

Can differences in promoter strength explain class II associations with disease?

An important question that needs to be addressed is whether allele specific sequence variation affecting expression can provide a mechanism for class II associated diseases. A large number of self-antigens are expressed at highly variable levels in the thymic epithelium.⁹² Given the quantitative nature of the thymic selection processes,⁹³ a general reduction in the expression of the disease associated class II alleles in the thymus could

result in loss of central tolerance where thymocytes with excessive reactivity to self-antigens escape elimination.

However, the association of particular autoimmune diseases with several different MHC class II alleles makes it unlikely that the observed hierarchy of class II promoter strengths alone can account for class II associations with autoimmunity. For example, a predominant role of *HLA-DRB1**03, *04, *13 and *15 alleles in susceptibility to multiple sclerosis has been observed in various populations.⁹⁴⁻⁹⁸ These alleles have promoters of different apparent strengths, indicating several haplotypes can contribute to the same autoimmune disease. If expression is important in disease aetiology, it is more likely an additional layer of complexity enables tissue and/or timing specific MHC class II gene regulation in autoimmune diseases resulting in variable levels of class II molecules.

Support for such a model comes from analysis of a variable number tandem repeat (VNTR) polymorphism found upstream of the *INS* insulin gene, shorter (class I) alleles of which are associated with increased susceptibility to type 1 diabetes.^{99,100} Intriguingly, there was evidence of tissue specific differences in differential allelic expression between the short and long alleles of this VNTR with the disease-associated class I alleles showing increased expression in pancreatic islet cells using a number of different approaches but reduced expression in the thymic epithelium.¹⁰¹⁻¹⁰⁴ Similarly, *cis*-regulatory elements in the S, X and Y boxes or flanking regions may interact with tissue and/or timing specific regulatory factors to enable local control of class II expression resulting in tissue type dominance. There is evidence to support the concept of tissue type dominance in relation to regulatory variation from studies of the *HLA-DQB1* promoter region, where the relative expression levels associated with *0301 and *0302 haplotypes was reversed in different cell types.⁸⁶ This reinforces the view that future analysis aiming to define functionally important MHC class II alleles will need to carefully consider the context specificity within which particular variants may be acting including cell type, stage of differentiation and stimulus.

Global effects on MHC class II gene expression acting in a non allele-specific manner may also play an important role in disease susceptibility to infectious diseases. Many viruses reduce MHC class II expression to avoid protective immune responses. For example, *Chlamydia trachomatis* has been found to inhibit IFN- γ induced CIITA expression and therefore MHC class II gene expression, by causing degradation of the transcription factor Upstream Stimulatory Factor 1 (USF-1).¹⁰⁵ Moreover, the lack of MHC class II gene expression among patients with BLS is associated with reduced positive selection of CD4⁺ T cells in the thymus and inability of mature CD4⁺ cells to respond to antigens in the periphery.³¹ As a result, patients suffer from severe and recurrent bacterial and viral infections. Infectious diseases also provide many examples of specific associations with particular MHC class II haplotypes such as *HLA-DR2* in tuberculosis and leprosy¹⁰⁶ where the functional basis for observed allelic risk remain unclear, but environmental influences on MHC class II gene expression may provide some insight.

Environmental factors in MHC class II gene regulation

Several possible mechanisms can contribute to determining temporal and/or tissue specific differences in MHC class II expression. These include epigenetic mechanisms, cell-type specific enhancers or regulatory factors as well as the environment. To illustrate this, we consider here vitamin D and its relationship to MHC class II gene expression and disease. Vitamin D has long been known to exhibit immunomodulatory actions and early studies provided some evidence for an effect of vitamin D on MHC class II gene expression, although no specific mechanism was characterized.¹⁰⁷

Ultraviolet radiation dependent metabolism provides the major source of vitamin D in humans but at high latitudes solar radiation is too low to produce adequate levels of vitamin D, particularly in the winter.^{108, 109} As a result, vitamin D deficiency is associated with numerous autoimmune and infectious diseases. For instance, the world-wide distribution of reduced UVB radiation mirrors that of MS prevalence^{110, 111} and MS patients have significantly low circulating vitamin D levels during their adolescence compared to healthy controls.¹¹² Similarly, associations between vitamin D deficiency and TB susceptibility were described over 20 years ago¹¹³ and there is a good correlation between active disease and low vitamin D levels in TB.¹¹⁴

Vitamin D acts in the body through binding to its receptor (VDR). Once this ligand-receptor complex is internalized, it forms a heterodimer with the retinoid X receptor and acts as a transcription factor, binding to vitamin D response elements (VDREs) in the promoter region of several nuclear genes.¹¹⁵ Variation in vitamin D levels due to latitude and season enable differences in expression of vitamin D responsive genes to be manifested and provide an elegant candidate for triggering autoimmunity. This is supported by the finding that the vitamin D receptor is expressed in the thymus¹¹⁶ and peripheral mononuclear cells.¹¹⁷

We have recently shown how genetic variation defines a functional vitamin D response element (VDRE) in the proximal promoter of *HLA-DRB1* (Figure 5).¹¹⁸ Strikingly, this VDRE showed haplotype-specific differences, being highly conserved in the major MS associated haplotype *HLA-DRB1*1501* in Northern European populations, but disrupted to varying degrees in non-disease associated haplotypes. Functional assays showed that this VDRE can influence gene expression, conferring vitamin D sensitivity to the *HLA-DRB1*1501* haplotype. It is important to note that the extent of sequence diversity at this site remains to be defined and other haplotypes relevant to MHC class II associated diseases may harbour conserved VDREs.

The role of this interaction in disease aetiology remains to be discovered but it is plausible that lack of vitamin D in early childhood can affect allele-specific expression in the thymus resulting in loss of central tolerance and perhaps increasing the risk of autoimmunity in later life. At this point this is speculative and further work is needed. However it is intriguing that TB and leprosy patients have genetic associations with the VDR itself and/or are deficient in vitamin D,^{119, 120} this can result in reduced expression of the disease associated *HLA-DR2* alleles (which include *HLA-DRB1*1501*) perhaps providing a mechanism as to how protective immune responses are bypassed.

Other factors such as estradiol have been shown to down regulate MHC class II gene expression.^{117, 121} This may be of particular interest to autoimmunity given that a lower age at puberty is a known risk factor for women¹²² and the observed sexual dimorphism in many autoimmune diseases.¹²³

The insulator factor CTCF and MHC class II gene regulation

Recent studies of transcriptional regulation have highlighted how gene expression is regulated in a complex three-dimensional system in which spatial organisation of chromatin plays an important role.^{124, 125} This raises the question of which factors control nuclear organisation and long-range chromosomal interactions. One leading candidate is CCCTC-binding factor (CTCF), a highly conserved and ubiquitously expressed 11 zinc finger protein.¹²⁶ CTCF was initially identified as a transcriptional repressor but subsequently shown to also activate transcription and have a much more fundamental and global role as a transcriptional insulator, acting as a position dependent enhancer blocking protein¹²⁷ and binding to boundary elements to prevent spreading of heterochromatin.¹²⁸ Moreover, CTCF has been shown to play a critical role in mediating inter- and intra-chromosomal

interactions through chromosomal looping with diverse roles in transcriptional regulation dependent for example on specific interacting proteins.¹²⁶ This includes the regulation of allele specific expression patterns at imprinted gene loci such as *H19/IGF2* relating to methylation status.^{129,132}

A recent study elegantly provides evidence for a novel CTCF-dependent MHC class II mechanism of gene regulation, where the expression of *HLA-DRB1* and *HLA-DQA* is dependent on an intergenic X-box like sequence dubbed XL9 located 29 kb centromeric to *HLA-DRB1*. Similar to XL sequences discussed earlier, XL9 displays a histone modification profile that is associated with accessible chromatin involving histone acetylation extending several kilobases from the site.¹³³ The region of peak acetylation was found to be bound by CTCF and functioned as an enhancer blocking element. Majumder and colleagues more recently provided evidence for long-range chromatin loops between the promoters of *HLA-DRB1* and *HLA-DQA* and XL9.¹³⁴ Strikingly, these interactions were dependent on the activity of CTCF, CIITA and RFX, either constitutively or after induction with IFN γ in non-expressing cells. Indeed, CTCF siRNA knock down was found to reduce the long-range interactions and decrease expression of *HLA-DRB1* and *HLA-DQA*.¹³⁴

These findings suggest a novel regulatory mechanism dependent on CTCF, whereby both *HLA-DRB1* and *HLA-DQA* loci can interact simultaneously with XL9. This replaces the outdated linear model of gene regulation with a three dimensional model in which long range intrachromosomal associations orchestrate MHC class II regulation. In general, the *HLA-DR* and *HLA-DQ* genes are thought to be co-regulated, however they can be discordantly regulated for example in certain non-Hodgkin's lymphomas.¹³⁵ It is possible that aberrant regulation of the XL9 element may allow these differences to be manifested.

It will be intriguing to investigate whether genetic variation exists in this CTCF binding site. Such variation could give rise to decreased or dysregulated expression of *HLA-DRB1* and *HLA-DQA1* and perhaps contribute to MHC class II associations with disease. Moreover, recent genome-wide analyses of CTCF binding in human cells have identified several other CTCF binding sites in the class II region^{136,138} suggesting that multiple CTCF sites may serve to coordinate the expression of nearby class II genes and be candidates for the site of action of regulatory variants.

Missing pieces in the regulation of MHC class II gene expression

In the past decade, we have acquired a remarkably detailed understanding of how MHC class II genes are regulated. As discussed in this review, studies to date have focused on *cis*-regulatory elements in the context of DNA sequence variation. It is becoming increasingly clear however that processes such as epigenetic modifications and noncoding RNAs are also central players in gene regulation.¹³⁹ Given that a full explanation for most MHC class II associations with disease has not been reached, it seems rational to explore the potential contribution of such mechanisms to MHC class II gene expression.

Epigenetics refers to processes such as DNA methylation and histone modifications that act as local chemical marks on the DNA to regulate gene activity and, in the stricter definition of the term, result in heritable effects independently of any changes in the DNA sequence.^{140,141} Combinations of these epigenetic changes modulate the accessibility of regulatory DNA sequences to transcription factors and may contribute to the cell-type specific expression of class II genes. Furthermore, the recognition that methylation marks are prone to disease-related alterations makes them prime targets in epigenetic analysis and expression studies.¹⁴² Interest in this field has gained great momentum with the recent realisation that epigenetics may underpin gene-environment interactions and that the resulting expression changes could be a major way of adapting to external influences.^{143,144} Given the pivotal

role that the MHC class II region plays in autoimmune disease, modulation of epigenetic regulation of class II gene expression by environmental factors is likely to be an important mechanism in disease pathogenesis. So far reports investigating the methylation profiles across the classical MHC including the class II region demonstrate tissue specific and bimodally distributed patterns of methylation.^{145,146} However, to date a complete analysis of methylation profiles in the MHC class II accounting for haplotypic variation has not been carried out.

Epigenetic regulation involving covalent modifications such as histone acetylation and methylation play a critical role in activation of MHC class II genes while gene silencing through for example histone deacetylation are also fundamentally important as seen elsewhere in the genome.¹⁴⁷ There are however unique features to MHC class II genes relating to their particular mode of regulation, notably the role of CIITA in recruitment of histone acetyltransferases (HATs).¹⁴⁸ CIITA can associate with multiple HATs, including CBP/p300 as well as other HATs such as steroid receptor coactivator (SRC1).¹⁴⁹ Intriguingly, this provides a mechanism by which hormones such as estrogens and glucocorticoids could regulate MHC class II genes. As well as the key role of CIITA in histone acetylation,¹⁵⁰ CIITA is also critical to recruitment of ATP-dependent chromatin remodelling complexes; there is also evidence for a role for CIITA and RFX in recruitment of histone deacetylases (HDACs) (reviewed in¹⁴⁷).

Regulation of CIITA gene expression is itself controlled by epigenetic mechanisms including DNA methylation and histone modifications.¹⁴⁷ These can in turn be modulated by environmental factors such as infectious pathogens. Indeed, *Mycobacterial* infection may inhibit the host immune response through such epigenetic mechanisms, *Mycobacterium tuberculosis* for example inhibiting IFN γ induced CIITA expression through effects on promoter histone acetylation and so reducing MHC class II expression.^{151,152}

Alternative splicing, the process whereby multiple mRNAs may be generated from individual genes, adds another dimension to the regulation of gene expression and considerably expands the versatility of the transcriptome to result in significant proteomic diversity.^{153,154} It is possible genetic variation in the class II region affects splicing efficiency and alters either the total output of a gene or the ratio of alternatively spliced variants. Indeed, haplotype-specific splicing patterns of the *HLA-DQB1* gene have been observed and mapped to specific single nucleotide substitutions within intron 3. These variants were located in a regulatory sequence controlling splicing, specifically a branch point sequence, that altered the binding affinity of splicing factor 1 and led to exclusion of exon 4 for *HLA-DQB1**0302 and *0401.¹⁵⁵ Similarly, several other class II loci including *HLA-DRB1* and *HLA-DQA1* are known to exhibit haplotypic variation at splice sites, which may affect expression at a post-transcriptional level.¹⁵⁶ A growing number of reports highlight the role of DNA sequence variation in modulating alternative splicing which can contribute to disease susceptibility.¹⁵⁷

The MHC class II region has already provided one of the clearest examples of a SNP modulating alternative splicing resulting in common disease through the work of Valentonyte and colleagues on genetic determinants of sarcoidosis, a chronic granulomatous condition.¹⁵⁸ A genome-wide linkage and association analysis resolved variants at *BTNL2* (butyrophilin-like 2, a member of the immunoglobulin family) in disease susceptibility and more specifically a G to A nucleotide substitution (rs2076530) within exon 5 which created an alternative splice site, and led to a frameshift and premature stop. The truncated protein associated with the A allele loses its membrane localisation ability which is thought to affect the ability of BTNL2 to regulate T cell activation.¹⁵⁹ Further characterization of the MHC

class II transcriptome and splicing code in the light of sequence diversity may therefore shed light on the molecular basis for class II associations with disease.

Furthermore, it has recently come to light that a family of small non-coding RNAs known as microRNAs (miRNAs) can negatively regulate gene expression by suppressing translation or degrading mRNA transcripts.¹⁶⁰ These miRNAs have important and diversified functions including cell differentiation¹⁶¹, tumorigenesis¹⁶² and viral defence.¹⁶³ As a result, the possibility that class II gene expression could be regulated by miRNAs, and more specifically, differentially regulated based on underlying sequence variation, needs to be examined. An elegant example of how such a mechanism may be involved in gene regulation comes from the MHC class I gene *HLA-G* and variants implicated in susceptibility to asthma. A SNP in the 3' UTR of *HLA-G* influences the targeting of three miRNAs and therefore affects *HLA-G* protein expression in an allele-specific manner.¹⁶⁴

Conclusion

The emerging evidence that regulation of gene expression is much more complex than previously thought has significant implications for disease associated MHC class II genes. Identification of regulatory genetic variants involving this region requires further detailed investigation taking into account current insights into coordinate regulation involving proximal and distal elements, intergenic regions and chromosomal looping, epigenetic mechanisms and environmental factors determining cell, differentiation state and stimulus specific gene expression. Although the focus in this review has been on how class II gene expression can be regulated at the transcriptional level, it is known that post-transcriptional modifications affecting the cytoplasmic tail of class II molecules may alter their export to the cell surface.¹⁶⁵ Clearly, we still have much more to learn about how gene expression is regulated in the class II region. Technological advances should continue to improve our ability to characterise class II expression including for example at single cell resolution *in vivo*, allowing analysis in disease-specific cell types and hopefully unlocking some of the mysteries that have long surrounded MHC class II genetic associations with autoimmune and infectious diseases.

Acknowledgments

The authors would like to thank all members of the Ebers and Knight laboratories together with members of Canadian Collaborative Project on the Genetic Susceptibility to Multiple Sclerosis.

Funding: J.C.K. is a Wellcome Trust Senior Research Fellow in Clinical Science. G.C.E. is the Action Research Professor of Clinical Neurology at University of Oxford. The Medical Research Council of the United Kingdom funds L.H. This research is also funded by the Multiple Sclerosis Society.

References

1. Watts C. The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. *Nat Immunol.* 2004; 5:685–692. [PubMed: 15224094]
2. Kyewski B, Klein L. A central role for central tolerance. *Annu Rev Immunol.* 2006; 24:571–606. [PubMed: 16551260]
3. Winchester R, Ebers G, Fu SM, Espinosa L, Zabriskie J, Kunkel HG. B-cell alloantigen Ag 7a in multiple sclerosis. *Lancet.* 1975; 2:814. [PubMed: 78174]
4. Jersild C, Svejgaard A, Fog T. HL-A antigens and multiple sclerosis. *Lancet.* 1972; 1:1240–1241. [PubMed: 4113225]
5. Cudworth AG, Woodrow JC. Evidence for HL-A-linked genes in “juvenile” diabetes mellitus. *Br Med J.* 1975; 3:133–135. [PubMed: 1139259]

6. Nerup J, Platz P, Andersen OO, Christy M, Lyngsoe J, Poulsen JE, et al. HL-A antigens and diabetes mellitus. *Lancet*. 1974; 2:864–866. [PubMed: 4137711]
7. Falchuk ZM, Rogentine GN, Strober W. Predominance of histocompatibility antigen HL-A8 in patients with gluten-sensitive enteropathy. *J Clin Invest*. 1972; 51:1602–1605. [PubMed: 5024049]
8. Stokes PL, Asquith P, Holmes GK, Mackintosh P, Cooke WT. Histocompatibility antigens associated with adult coeliac disease. *Lancet*. 1972; 2:162–164. [PubMed: 4114064]
9. Kagnoff MF. Celiac disease: pathogenesis of a model immunogenetic disease. *J Clin Invest*. 2007; 117:41–49. [PubMed: 17200705]
10. Todd JA, Bell JI, McDevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. *Nature*. 1987; 329:599–604. [PubMed: 3309680]
11. WTCCC. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*. 2007; 447:661–678. [PubMed: 17554300]
12. Gregersen PK, Behrens TW. Genetics of autoimmune diseases--disorders of immune homeostasis. *Nat Rev Genet*. 2006; 7:917–928. [PubMed: 17139323]
13. de Bakker PI, McVean G, Sabeti PC, Miretti MM, Green T, Marchini J, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. *Nat Genet*. 2006; 38:1166–1172. [PubMed: 16998491]
14. Vandiedonck C, Knight JC. The human Major Histocompatibility Complex as a paradigm in genomics research. *Brief Funct Genomic Proteomic*. 2009 doi:10.1093/bfgp/elp010.
15. Knight, JC. Human Genetic Diversity. Functional Consequences for Health and Disease. First edn.. Oxford University Press; Oxford: 2009.
16. Jones EY, Fugger L, Strominger JL, Siebold C. MHC class II proteins and disease: a structural perspective. *Nat Rev Immunol*. 2006; 6:271–282. [PubMed: 16557259]
17. Ramagopalan SV, McMahon R, Dymant DA, Sadovnick AD, Ebers GC, Wittkowski KM. An extension to a statistical approach for family based association studies provides insights into genetic risk factors for multiple sclerosis in the HLA-DRB1 gene. *BMC medical genetics*. 2009; 10:10. [PubMed: 19193207]
18. Dixon AL, Liang L, Moffatt MF, Chen W, Heath S, Wong KC, et al. A genome-wide association study of global gene expression. *Nat Genet*. 2007; 39:1202–1207. [PubMed: 17873877]
19. Horton R, Wilming L, Rand V, Lovering RC, Bruford EA, Khodiyar VK, et al. Gene map of the extended human MHC. *Nat Rev Genet*. 2004; 5:889–899. [PubMed: 15573121]
20. Beck S, Trowsdale J. Sequence organisation of the class II region of the human MHC. *Immunol Rev*. 1999; 167:201–210. [PubMed: 10319262]
21. Alfonso C, Karlsson L. Nonclassical MHC class II molecules. *Annu Rev Immunol*. 2000; 18:113–142. [PubMed: 10837054]
22. Pieters J. MHC class II-restricted antigen processing and presentation. *Adv Immunol*. 2000; 75:159–208. [PubMed: 10879284]
23. Reith W, LeibundGut-Landmann S, Waldburger JM. Regulation of MHC class II gene expression by the class II transactivator. *Nat Rev Immunol*. 2005; 5:793–806. [PubMed: 16200082]
24. Chang CH, Hong SC, Hughes CC, Janeway CA Jr, Flavell RA. CIITA activates the expression of MHC class II genes in mouse T cells. *Int Immunol*. 1995; 7:1515–1518. [PubMed: 7495759]
25. Baecher-Allan C, Wolf E, Hafler DA. MHC class II expression identifies functionally distinct human regulatory T cells. *J Immunol*. 2006; 176:4622–4631. [PubMed: 16585553]
26. Manjuck J, Saha DC, Astiz M, Eales LJ, Rackow EC. Decreased response to recall antigens is associated with depressed costimulatory receptor expression in septic critically ill patients. *J Lab Clin Med*. 2000; 135:153–160. [PubMed: 10695660]
27. Pachot A, Monneret G, Brion A, Venet F, Bohe J, Bienvenu J, et al. Messenger RNA expression of major histocompatibility complex class II genes in whole blood from septic shock patients. *Crit Care Med*. 2005; 33:31–38. discussion 236–237. [PubMed: 15644645]
28. Monneret G, Lepape A, Voirin N, Bohe J, Venet F, Debard AL, et al. Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. *Intensive Care Med*. 2006; 32:1175–1183. [PubMed: 16741700]

29. Rimsza LM, Roberts RA, Miller TP, Unger JM, LeBlanc M, Brazier RM, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. *Blood*. 2004; 103:4251–4258. [PubMed: 14976040]
30. Mach B, Steimle V, Martinez-Soria E, Reith W. Regulation of MHC class II genes: lessons from a disease. *Annu Rev Immunol*. 1996; 14:301–331. [PubMed: 8717517]
31. Reith W, Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. *Annu Rev Immunol*. 2001; 19:331–373. [PubMed: 11244040]
32. Boss JM, Jensen PE. Transcriptional regulation of the MHC class II antigen presentation pathway. *Curr Opin Immunol*. 2003; 15:105–111. [PubMed: 12495741]
33. Harton JA, Ting JP. Class II transactivator: mastering the art of major histocompatibility complex expression. *Mol Cell Biol*. 2000; 20:6185–6194. [PubMed: 10938095]
34. Accolla RS, Jotterand-Bellomo M, Scarpellino L, Maffei A, Carra G, Guardiola J. *alr-1*, a newly found locus on mouse chromosome 16 encoding a trans-acting activator factor for MHC class II gene expression. *J Exp Med*. 1986; 164:369–374. [PubMed: 3088202]
35. Steimle V, Durand B, Barras E, Zufferey M, Hadam MR, Mach B, et al. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome). *Genes Dev*. 1995; 9:1021–1032. [PubMed: 7744245]
36. Durand B, Sperisen P, Emery P, Barras E, Zufferey M, Mach B, et al. RFXAP, a novel subunit of the RFX DNA binding complex is mutated in MHC class II deficiency. *EMBO J*. 1997; 16:1045–1055. [PubMed: 9118943]
37. Masternak K, Barras E, Zufferey M, Conrad B, Corthals G, Aebersold R, et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. *Nat Genet*. 1998; 20:273–277. [PubMed: 9806546]
38. Steimle V, Otten LA, Zufferey M, Mach B. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome). *Cell*. 1993; 75:135–146. [PubMed: 8402893]
39. Briggs L, Laird K, Boss JM, Garvie CW. Formation of the RFX gene regulatory complex induces folding of the interaction domain of RFXAP. *Proteins*. 2009; 76:655–664. [PubMed: 19274739]
40. Moreno CS, Beresford GW, Louis-Plence P, Morris AC, Boss JM. CREB regulates MHC class II expression in a CIITA-dependent manner. *Immunity*. 1999; 10:143–151. [PubMed: 10072067]
41. Mantovani R, Pessara U, Tronche F, Li XY, Knapp AM, Pasquali JL, et al. Monoclonal antibodies to NF-Y define its function in MHC class II and albumin gene transcription. *EMBO J*. 1992; 11:3315–3322. [PubMed: 1380453]
42. Seguin-Estevez Q, De Palma R, Krawczyk M, Leimgruber E, Villard J, Picard C, et al. The Transcription Factor RFX Protects MHC Class II Genes against Epigenetic Silencing by DNA Methylation. *J Immunol*. 2009
43. Ting JP, Trowsdale J. Genetic control of MHC class II expression. *Cell*. 2002; 109(Suppl):S21–33. [PubMed: 11983150]
44. Muhlethaler-Mottet A, Krawczyk M, Masternak K, Spilianakis C, Kretsovali A, Papamatheakis J, et al. The S box of major histocompatibility complex class II promoters is a key determinant for recruitment of the transcriptional co-activator CIITA. *J Biol Chem*. 2004; 279:40529–40535. [PubMed: 15271997]
45. Muhlethaler-Mottet A, Otten LA, Steimle V, Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. *EMBO J*. 1997; 16:2851–2860. [PubMed: 9184229]
46. Hakonarson H, Grant SF, Bradfield JP, Marchand L, Kim CE, Glessner JT, et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. *Nature*. 2007; 448:591–594. [PubMed: 17632545]
47. Todd JA, Walker NM, Cooper JD, Smyth DJ, Downes K, Plagnol V, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. *Nat Genet*. 2007; 39:857–864. [PubMed: 17554260]

48. Swanberg M, Lidman O, Padyukov L, Eriksson P, Akesson E, Jagodic M, et al. MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. *Nat Genet.* 2005; 37:486–494. [PubMed: 15821736]
49. Akkad DA, Jagiello P, Szyld P, Goedde R, Wiczorek S, Gross WL, et al. Promoter polymorphism rs3087456 in the MHC class II transactivator gene is not associated with susceptibility for selected autoimmune diseases in German patient groups. *International journal of immunogenetics.* 2006; 33:59–61. [PubMed: 16426246]
50. Eyre S, Bowes J, Spreckley K, Potter C, Ring S, Strachan D, et al. Investigation of the MHC2TA gene, associated with rheumatoid arthritis in a Swedish population, in a UK rheumatoid arthritis cohort. *Arthritis Rheum.* 2006; 54:3417–3422. [PubMed: 17075826]
51. Harrison P, Pointon JJ, Farrar C, Harin A, Wordsworth BP. MHC2TA promoter polymorphism (-168*G/A, rs3087456) is not associated with susceptibility to rheumatoid arthritis in British Caucasian rheumatoid arthritis patients. *Rheumatology (Oxford).* 2007; 46:409–411. [PubMed: 16920747]
52. Olsson T, Jagodic M, Piehl F, Wallstrom E. Genetics of autoimmune neuroinflammation. *Curr Opin Immunol.* 2006; 18:643–649. [PubMed: 16973343]
53. Bronson PG, Criswell LA, Barcellos LF. The MHC2TA -168A/G polymorphism and risk for rheumatoid arthritis: a meta-analysis of 6861 patients and 9270 controls reveals no evidence for association. *Ann Rheum Dis.* 2008; 67:933–936. [PubMed: 17875550]
54. Dorn A, Fehling HJ, Koch W, Le Meur M, Gerlinger P, Benoist C, et al. B-cell control region at the 5' end of a major histocompatibility complex class II gene: sequences and factors. *Mol Cell Biol.* 1988; 8:3975–3987. [PubMed: 3141781]
55. Carson S, Wiles MV. Far upstream regions of class II MHC Ea are necessary for position-independent, copy-dependent expression of Ea transgene. *Nucleic Acids Res.* 1993; 21:2065–2072. [PubMed: 8502547]
56. van Ewijk W, Ron Y, Monaco J, Kappler J, Marrack P, Le Meur M, et al. Compartmentalization of MHC class II gene expression in transgenic mice. *Cell.* 1988; 53:357–370. [PubMed: 3259162]
57. Feriotto G, Mischiati C, Bianchi N, Rutigliano C, Giacomini P, Gambari R. Sequencing of an upstream region of the human HLA-DRA gene containing X' and Y' boxes. *Nucleic Acids Res.* 1995; 23:1671–1678. [PubMed: 7784170]
58. Masternak K, Peyraud N, Krawczyk M, Barras E, Reith W. Chromatin remodeling and extragenic transcription at the MHC class II locus control region. *Nat Immunol.* 2003; 4:132–137. [PubMed: 12524537]
59. Krawczyk M, Peyraud N, Rybtsova N, Masternak K, Bucher P, Barras E, et al. Long distance control of MHC class II expression by multiple distal enhancers regulated by regulatory factor X complex and CIITA. *J Immunol.* 2004; 173:6200–6210. [PubMed: 15528357]
60. Gomez JA, Majumder P, Nagarajan UM, Boss JM. X box-like sequences in the MHC class II region maintain regulatory function. *J Immunol.* 2005; 175:1030–1040. [PubMed: 16002703]
61. von Salome J, Gyllensten U, Bergstrom TF. Full-length sequence analysis of the HLA-DRB1 locus suggests a recent origin of alleles. *Immunogenetics.* 2007; 59:261–271. [PubMed: 17345114]
62. Andersson G. Evolution of the human HLA-DR region. *Front Biosci.* 1998; 3:d739–745. [PubMed: 9675159]
63. Trowsdale J. “Both man & bird & beast”: comparative organization of MHC genes. *Immunogenetics.* 1995; 41:1–17. [PubMed: 7806269]
64. Hughes AL, Nei M. Nucleotide substitution at major histocompatibility complex class II loci: evidence for overdominant selection. *Proc Natl Acad Sci U S A.* 1989; 86:958–962. [PubMed: 2492668]
65. Loisel DA, Rockman MV, Wray GA, Altmann J, Alberts SC. Ancient polymorphism and functional variation in the primate MHC-DQA1 5' cis-regulatory region. *Proc Natl Acad Sci U S A.* 2006; 103:16331–16336. [PubMed: 17053068]
66. Liu X, Fu Y, Liu Z, Lin B, Xie Y, Liu Y, et al. An ancient balanced polymorphism in a regulatory region of human major histocompatibility complex is retained in Chinese minorities but lost worldwide. *Am J Hum Genet.* 2006; 78:393–400. [PubMed: 16465617]

67. Leen MP, Ogutu ER, Gorski J. Structural and functional analysis of HLA-DR beta-promoter polymorphism and isomorphism. *Hum Immunol.* 1994; 41:112–120. [PubMed: 7860355]
68. Perfetto C, Zacheis M, McDaid D, Meador JW 3rd, Schwartz BD. Polymorphism in the promoter region of HLA-DRB genes. *Hum Immunol.* 1993; 36:27–33. [PubMed: 8458736]
69. Singal DP, Qiu X, D'Souza M, Sood SK. Polymorphism in the upstream regulatory regions of HLA-DRB genes. *Immunogenetics.* 1993; 37:143–147. [PubMed: 8423054]
70. Louis P, Eliaou JF, Kerlan-Candon S, Pinet V, Vincent R, Clot J. Polymorphism in the regulatory region of HLA-DRB genes correlating with haplotype evolution. *Immunogenetics.* 1993; 38:21–26. [PubMed: 8462990]
71. Singal DP, D'Souza M, Sood SK, Qiu X. Sequence-specific interactions of the nuclear proteins with polymorphic upstream regulatory regions of HLA-DRB genes. *Transplantation proceedings.* 1993; 25:180–182. [PubMed: 8438265]
72. Emery P, Mach B, Reith W. The different level of expression of HLA-DRB1 and -DRB3 genes is controlled by conserved isotypic differences in promoter sequence. *Hum Immunol.* 1993; 38:137–147. [PubMed: 8106268]
73. Louis P, Vincent R, Cavadore P, Clot J, Eliaou JF. Differential transcriptional activities of HLA-DR genes in the various haplotypes. *J Immunol.* 1994; 153:5059–5067. [PubMed: 7963565]
74. Singal DP, Qiu X. Polymorphism in both X and Y box motifs controls level of expression of HLA-DRB1 genes. *Immunogenetics.* 1996; 43:50–56. [PubMed: 8537121]
75. Sindwani S, Singal DP. Polymorphism in the Y box controls level of cytokine-mediated expression of HLA-DRB1 genes. *Tissue Antigens.* 2001; 58:315–323. [PubMed: 11844142]
76. Louis P, Pinet V, Cavadore P, Kerlan-Candon S, Clot J, Eliaou JF. Differential expression of HLA-DRB genes according to the polymorphism of their regulatory region. *C R Acad Sci III.* 1994; 317:161–166. [PubMed: 7994605]
77. Vincent R, Louis-Plence P, Gaillard F, Clot J, Eliaou JF. Qualitative and quantitative analysis of HLA-DRB gene expression. *J Rheumatol.* 1997; 24:225–226. [PubMed: 9002047]
78. Singal DP, Qiu X. Polymorphism in the upstream regulatory region and level of expression of HLA-DRB genes. *Mol Immunol.* 1994; 31:1117–1120. [PubMed: 7523867]
79. Vincent R, Louis P, Gongora C, Papa I, Clot J, Eliaou JF. Quantitative analysis of the expression of the HLA-DRB genes at the transcriptional level by competitive polymerase chain reaction. *J Immunol.* 1996; 156:603–610. [PubMed: 8543811]
80. Kerlan-Candon S, Combe B, Vincent R, Clot J, Pinet V, Eliaou JF. HLA-DRB1 gene transcripts in rheumatoid arthritis. *Clin Exp Immunol.* 2001; 124:142–149. [PubMed: 11359453]
81. Leen MP, Gorski J. Differential expression of isomorphic HLA-DR beta genes is not a sole function of transcription. *Hum Immunol.* 1996; 50:111–120. [PubMed: 8891734]
82. Janitz M, Mitchison A, Reiners-Schramm L, Lauster R. Polymorphic MHC class II promoters exhibit distinct expression pattern in various antigen-presenting cell lines. *Tissue Antigens.* 1997; 49:99–106. [PubMed: 9062963]
83. Baumgart M, Moos V, Schuhbauer D, Muller B. Differential expression of major histocompatibility complex class II genes on murine macrophages associated with T cell cytokine profile and protective/suppressive effects. *Proc Natl Acad Sci U S A.* 1998; 95:6936–6940. [PubMed: 9618517]
84. Bontrop R, Ottenhoff T, Van Miltenburg R, Elferink D, De Vries R, Giphart M. Quantitative and qualitative differences in HLA-DR molecules correlated with antigen-presentation capacity. *Eur J Immunol.* 1986; 16:133–138. [PubMed: 3485528]
85. Irle C, Jaques D, Tiercy JM, Fuggle SV, Gorski J, Termijtelen A, et al. Functional polymorphism of each of the two HLA-DR beta chain loci demonstrated with antigen-specific DR3- and DRw52-restricted T cell clones. *J Exp Med.* 1988; 167:853–872. [PubMed: 2450955]
86. Beaty JS, Sukiennicki TL, Nepom GT. Allelic variation in transcription modulates MHC class II expression and function. *Microbes Infect.* 1999; 1:919–927. [PubMed: 10614010]
87. Andersen LC, Beaty JS, Nettles JW, Seyfried CE, Nepom GT, Nepom BS. Allelic polymorphism in transcriptional regulatory regions of HLA-DQB genes. *J Exp Med.* 1991; 173:181–192. [PubMed: 1985121]

88. Ferstl B, Zacher T, Lauer B, Blagitko-Dorfs N, Carl A, Wassmuth R. Allele-specific quantification of HLA-DQB1 gene expression by real-time reverse transcriptase-polymerase chain reaction. *Genes Immun.* 2004; 5:405–416. [PubMed: 15175648]
89. Cesari M, Caillens H, Cadet F, Pabion M. In vivo analysis of HLA-DQ gene expression in heterozygous cell lines. *Immunogenetics.* 1999; 50:309–318. [PubMed: 10630295]
90. Nepom GT, Chung J, West KA. Differential expression of HLA-DQB1 alleles in a heterozygous cell line. *Immunogenetics.* 1995; 42:143–148. [PubMed: 7607705]
91. Beaty JS, West KA, Nepom GT. Functional effects of a natural polymorphism in the transcriptional regulatory sequence of HLA-DQB1. *Mol Cell Biol.* 1995; 15:4771–4782. [PubMed: 7651394]
92. Takase H, Yu CR, Mahdi RM, Douek DC, Dirusso GB, Midgley FM, et al. Thymic expression of peripheral tissue antigens in humans: a remarkable variability among individuals. *Int Immunol.* 2005; 17:1131–1140. [PubMed: 16030131]
93. Liston A, Lesage S, Gray DH, Boyd RL, Goodnow CC. Genetic lesions in T-cell tolerance and thresholds for autoimmunity. *Immunol Rev.* 2005; 204:87–101. [PubMed: 15790352]
94. Ramagopalan SV, Morris AP, Dymment DA, Herrera BM, DeLuca GC, Lincoln MR, et al. The inheritance of resistance alleles in multiple sclerosis. *PLoS Genet.* 2007; 3:1607–1613. [PubMed: 17845076]
95. Svejgaard A. The immunogenetics of multiple sclerosis. *Immunogenetics.* 2008; 60:275–286. [PubMed: 18461312]
96. Ramagopalan SV, Knight JC, Ebers GC. Multiple sclerosis and the major histocompatibility complex. *Curr Opin Neurol.* 2009; 22:219–225. [PubMed: 19387341]
97. Dymment DA, Herrera BM, Cader MZ, Willer CJ, Lincoln MR, Sadovnick AD, et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. *Hum Mol Genet.* 2005; 14:2019–2026. [PubMed: 15930013]
98. Modin H, Olsson W, Hillert J, Masterman T. Modes of action of HLA-DR susceptibility specificities in multiple sclerosis. *Am J Hum Genet.* 2004; 74:1321–1322. [PubMed: 15195659]
99. Bell GI, Horita S, Karam JH. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. *Diabetes.* 1984; 33:176–183. [PubMed: 6363172]
100. Bennett ST, Lucassen AM, Gough SC, Powell EE, Undlien DE, Pritchard LE, et al. Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. *Nat Genet.* 1995; 9:284–292. [PubMed: 7773291]
101. Pugliese A, Zeller M, Fernandez A Jr, Zalcberg LJ, Bartlett RJ, Ricordi C, et al. The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. *Nat Genet.* 1997; 15:293–297. [PubMed: 9054945]
102. Vafiadis P, Bennett ST, Todd JA, Nadeau J, Grabs R, Goodyer CG, et al. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. *Nat Genet.* 1997; 15:289–292. [PubMed: 9054944]
103. Cocozza S, Riccardi G, Monticelli A, Capaldo B, Genovese S, Krogh V, et al. Polymorphism at the 5' end flanking region of the insulin gene is associated with reduced insulin secretion in healthy individuals. *Eur J Clin Invest.* 1988; 18:582–586. [PubMed: 3147185]
104. Lucassen AM, Sreaton GR, Julier C, Elliott TJ, Lathrop M, Bell JI. Regulation of insulin gene expression by the IDDM associated, insulin locus haplotype. *Hum Mol Genet.* 1995; 4:501–506. [PubMed: 7633396]
105. Zhong G, Fan T, Liu L. Chlamydia inhibits interferon gamma-inducible major histocompatibility complex class II expression by degradation of upstream stimulatory factor 1. *J Exp Med.* 1999; 189:1931–1938. [PubMed: 10377188]
106. Frodsham AJ, Hill AV. Genetics of infectious diseases. *Hum Mol Genet.* 2004; 13:R187–194. Spec No 2. [PubMed: 15358724]
107. Rigby WF, Waugh M, Graziano RF. Regulation of human monocyte HLA-DR and CD4 antigen expression, and antigen presentation by 1,25-dihydroxyvitamin D3. *Blood.* 1990; 76:189–197. [PubMed: 2364169]

108. Vieth R, Cole DE, Hawker GA, Trang HM, Rubin LA. Wintertime vitamin D insufficiency is common in young Canadian women, and their vitamin D intake does not prevent it. *Eur J Clin Nutr.* 2001; 55:1091–1097. [PubMed: 11781676]
109. Kimlin MG. Geographic location and vitamin D synthesis. *Mol Aspects Med.* 2008; 29:453–461. [PubMed: 18786559]
110. Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Part one. *Acta neurologica Scandinavica.* 1975; 51:110–136. [PubMed: 46682]
111. van der Mei IA, Ponsonby AL, Blizzard L, Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. *Neuroepidemiology.* 2001; 20:168–174. [PubMed: 11490162]
112. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. *JAMA.* 2006; 296:2832–2838. [PubMed: 17179460]
113. Davies PD, Brown RC, Woodhead JS. Serum concentrations of vitamin D metabolites in untreated tuberculosis. *Thorax.* 1985; 40:187–190. [PubMed: 3872485]
114. Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. *Lancet.* 2000; 355:618–621. [PubMed: 10696983]
115. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. *Endocrine reviews.* 2005; 26:662–687. [PubMed: 15798098]
116. Stone LA, Weaver VM, Bruns ME, Welsh J. Vitamin D receptors in intestine, kidney and thymus of streptozotocin diabetic rats. *Diabetes research (Edinburgh, Scotland).* 1990; 15:165–172.
117. Veldman CM, Cantorna MT, DeLuca HF. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. *Archives of biochemistry and biophysics.* 2000; 374:334–338. [PubMed: 10666315]
118. Ramagopalan SV, Maugeri NJ, Handunnetthi L, Lincoln MR, Orton SM, Dymment DA, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. *PLoS Genet.* 2009; 5:e1000369. [PubMed: 19197344]
119. Bornman L, Campbell SJ, Fielding K, Bah B, Sillah J, Gustafson P, et al. Vitamin D receptor polymorphisms and susceptibility to tuberculosis in West Africa: a case-control and family study. *J Infect Dis.* 2004; 190:1631–1641. [PubMed: 15478069]
120. Chocano-Bedoya P, Ronnenberg AG. Vitamin D and tuberculosis. *Nutr Rev.* 2009; 67:289–293. [PubMed: 19386033]
121. Adamski J, Ma Z, Nozell S, Benveniste EN. 17beta-Estradiol inhibits class II major histocompatibility complex (MHC) expression: influence on histone modifications and cbp recruitment to the class II MHC promoter. *Mol Endocrinol.* 2004; 18:1963–1974. [PubMed: 15143155]
122. Ramagopalan SV, Valdar W, Criscuoli M, DeLuca GC, Dymment DA, Orton SM, et al. Age of puberty and the risk of multiple sclerosis: a population based study. *Eur J Neurol.* 2009; 16:342–347. [PubMed: 19170744]
123. Whitacre CC. Sex differences in autoimmune disease. *Nat Immunol.* 2001; 2:777–780. [PubMed: 11526384]
124. Sutherland H, Bickmore WA. Transcription factories: gene expression in unions? *Nat Rev Genet.* 2009; 10:457–466. [PubMed: 19506577]
125. Fraser P, Bickmore W. Nuclear organization of the genome and the potential for gene regulation. *Nature.* 2007; 447:413–417. [PubMed: 17522674]
126. Phillips JE, Corces VG. CTCF: master weaver of the genome. *Cell.* 2009; 137:1194–1211. [PubMed: 19563753]
127. Gaszner M, Felsenfeld G. Insulators: exploiting transcriptional and epigenetic mechanisms. *Nat Rev Genet.* 2006; 7:703–713. [PubMed: 16909129]
128. Burgess-Beusse B, Farrell C, Gaszner M, Litt M, Mutskov V, Recillas-Targa F, et al. The insulation of genes from external enhancers and silencing chromatin. *Proc Natl Acad Sci U S A.* 2002; 99(Suppl 4):16433–16437. [PubMed: 12154228]

129. Han L, Lee DH, Szabo PE. CTCF is the master organizer of domain-wide allele-specific chromatin at the H19/Igf2 imprinted region. *Mol Cell Biol.* 2008; 28:1124–1135. [PubMed: 18039862]
130. Ling JQ, Li T, Hu JF, Vu TH, Chen HL, Qiu XW, et al. CTCF mediates interchromosomal colocalization between Igf2/H19 and Wsb1/Nf1. *Science.* 2006; 312:269–272. [PubMed: 16614224]
131. Bell AC, Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. *Nature.* 2000; 405:482–485. [PubMed: 10839546]
132. Hark AT, Schoenherr CJ, Katz DJ, Ingram RS, Levorse JM, Tilghman SM. CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. *Nature.* 2000; 405:486–489. [PubMed: 10839547]
133. Majumder P, Gomez JA, Boss JM. The human major histocompatibility complex class II HLA-DRB1 and HLA-DQA1 genes are separated by a CTCF-binding enhancer-blocking element. *J Biol Chem.* 2006; 281:18435–18443. [PubMed: 16675454]
134. Majumder P, Gomez JA, Chadwick BP, Boss JM. The insulator factor CTCF controls MHC class II gene expression and is required for the formation of long-distance chromatin interactions. *J Exp Med.* 2008; 205:785–798. [PubMed: 18347100]
135. Smith ME, Holgate CS, Williamson JM, Grigor I, Quirke P, Bird CC. Major histocompatibility complex class II antigen expression in B and T cell non-Hodgkin's lymphoma. *Journal of clinical pathology.* 1987; 40:34–41. [PubMed: 3546388]
136. Cuddapah S, Jothi R, Schones DE, Roh TY, Cui K, Zhao K. Global analysis of the insulator binding protein CTCF in chromatin barrier regions reveals demarcation of active and repressive domains. *Genome Res.* 2009; 19:24–32. [PubMed: 19056695]
137. Kim TH, Abdullaev ZK, Smith AD, Ching KA, Loukinov DI, Green RD, et al. Analysis of the vertebrate insulator protein CTCF-binding sites in the human genome. *Cell.* 2007; 128:1231–1245. [PubMed: 17382889]
138. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, et al. High-resolution profiling of histone methylations in the human genome. *Cell.* 2007; 129:823–837. [PubMed: 17512414]
139. Kurokawa R, Rosenfeld MG, Glass CK. Transcriptional regulation through noncoding RNAs and epigenetic modifications. *RNA Biol.* 2009; 6
140. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. *Nat Rev Genet.* 2008; 9:465–476. [PubMed: 18463664]
141. Schones DE, Zhao K. Genome-wide approaches to studying chromatin modifications. *Nat Rev Genet.* 2008; 9:179–191. [PubMed: 18250624]
142. Wang SC, Oelze B, Schumacher A. Age-specific epigenetic drift in late-onset Alzheimer's disease. *PLoS ONE.* 2008; 3:e2698. [PubMed: 18628954]
143. Liu L, Li Y, Tollefsbol TO. Gene-environment interactions and epigenetic basis of human diseases. *Current issues in molecular biology.* 2008; 10:25–36. [PubMed: 18525104]
144. Jirtle RL, Skinner MK. Environmental epigenomics and disease susceptibility. *Nat Rev Genet.* 2007; 8:253–262. [PubMed: 17363974]
145. Rakyan VK, Hildmann T, Novik KL, Lewin J, Tost J, Cox AV, et al. DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome project. *PLoS Biol.* 2004; 2:e405. [PubMed: 15550986]
146. Tomazou EM, Rakyan VK, Lefebvre G, Andrews R, Ellis P, Jackson DK, et al. Generation of a genomic tiling array of the human Major Histocompatibility Complex (MHC) and its application for DNA methylation analysis. *BMC Med Genomics.* 2008; 1:19. [PubMed: 18513384]
147. Wright KL, Ting JP. Epigenetic regulation of MHC-II and CIITA genes. *Trends Immunol.* 2006; 27:405–412. [PubMed: 16870508]
148. Zika E, Ting JP. Epigenetic control of MHC-II: interplay between CIITA and histone-modifying enzymes. *Curr Opin Immunol.* 2005; 17:58–64. [PubMed: 15653312]
149. Tzortzakaki E, Spilianakis C, Zika E, Kretsovali A, Papamatheakis J. Steroid receptor coactivator 1 links the steroid and interferon gamma response pathways. *Mol Endocrinol.* 2003; 17:2509–2518. [PubMed: 12933903]

150. Beresford GW, Boss JM. CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter. *Nat Immunol.* 2001; 2:652–657. [PubMed: 11429551]
151. Pai RK, Convery M, Hamilton TA, Boom WH, Harding CV. Inhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from *Mycobacterium tuberculosis*: a potential mechanism for immune evasion. *J Immunol.* 2003; 171:175–184. [PubMed: 12816996]
152. Pennini ME, Pai RK, Schultz DC, Boom WH, Harding CV. *Mycobacterium tuberculosis* 19-kDa lipoprotein inhibits IFN-gamma-induced chromatin remodeling of MHC2TA by TLR2 and MAPK signaling. *J Immunol.* 2006; 176:4323–4330. [PubMed: 16547269]
153. Ben-Dov C, Hartmann B, Lundgren J, Valcarcel J. Genome-wide analysis of alternative pre-mRNA splicing. *J Biol Chem.* 2008; 283:1229–1233. [PubMed: 18024428]
154. Blencowe BJ. Alternative splicing: new insights from global analyses. *Cell.* 2006; 126:37–47. [PubMed: 16839875]
155. Kralovicova J, Houngrinou-Molango S, Kramer A, Vorechovsky I. Branch site haplotypes that control alternative splicing. *Hum Mol Genet.* 2004; 13:3189–3202. [PubMed: 15496424]
156. Horton R, Gibson R, Coggill P, Miretti M, Allcock RJ, Almeida J, et al. Variation analysis and gene annotation of eight MHC haplotypes: the MHC Haplotype Project. *Immunogenetics.* 2008; 60:1–18. [PubMed: 18193213]
157. Wang GS, Cooper TA. Splicing in disease: disruption of the splicing code and the decoding machinery. *Nat Rev Genet.* 2007; 8:749–761. [PubMed: 17726481]
158. Valentonyte R, Hampe J, Huse K, Rosenstiel P, Albrecht M, Stenzel A, et al. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. *Nat Genet.* 2005; 37:357–364. [PubMed: 15735647]
159. Nguyen T, Liu XK, Zhang Y, Dong C. BTNL2, a butyrophilin-like molecule that functions to inhibit T cell activation. *J Immunol.* 2006; 176:7354–7360. [PubMed: 16751379]
160. Boyd SD. Everything you wanted to know about small RNA but were afraid to ask. *Lab Invest.* 2008; 88:569–578. [PubMed: 18427554]
161. Johnston RJ, Hobert O. A microRNA controlling left/right neuronal asymmetry in *Caenorhabditis elegans*. *Nature.* 2003; 426:845–849. [PubMed: 14685240]
162. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. *Science.* 2004; 303:83–86. [PubMed: 14657504]
163. Lecellier CH, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C, et al. A cellular microRNA mediates antiviral defense in human cells. *Science.* 2005; 308:557–560. [PubMed: 15845854]
164. Tan Z, Randall G, Fan J, Camoretti-Mercado B, Brockman-Schneider R, Pan L, et al. Allele-specific targeting of microRNAs to HLA-G and risk of asthma. *Am J Hum Genet.* 2007; 81:829–834. [PubMed: 17847008]
165. Shin JS, Ebersold M, Pypaert M, Delamarre L, Hartley A, Mellman I. Surface expression of MHC class II in dendritic cells is controlled by regulated ubiquitination. *Nature.* 2006; 444:115–118. [PubMed: 17051151]
166. Iafrate AJ, Feuk L, Rivera MN, Listewnik ML, Donahoe PK, Qi Y, et al. Detection of large-scale variation in the human genome. *Nat Genet.* 2004; 36:949–951. [PubMed: 15286789]
167. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, et al. dbSNP: the NCBI database of genetic variation. *Nucleic Acids Res.* 2001; 29:308–311. [PubMed: 11125122]
168. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, et al. The human genome browser at UCSC. *Genome Res.* 2002; 12:996–1006. [PubMed: 12045153]
169. van Belzen MJ, Koeleman BP, Crusius JB, Meijer JW, Bardoel AF, Pearson PL, et al. Defining the contribution of the HLA region to cis DQ2-positive coeliac disease patients. *Genes Immun.* 2004; 5:215–220. [PubMed: 15014431]
170. Stokkers PC, Reitsma PH, Tytgat GN, van Deventer SJ. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. *Gut.* 1999; 45:395–401. [PubMed: 10446108]
171. Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR, et al. The molecular classification of the clinical manifestations of Crohn's disease. *Gastroenterology.* 2002; 122:854–866. [PubMed: 11910336]

172. Newman B, Silverberg MS, Gu X, Zhang Q, Lazaro A, Steinhart AH, et al. CARD15 and HLA DRB1 alleles influence susceptibility and disease localization in Crohn's disease. *Am J Gastroenterol.* 2004; 99:306–315. [PubMed: 15046222]
173. Ahmad T, Marshall SE, Jewell D. Genetics of inflammatory bowel disease: the role of the HLA complex. *World J Gastroenterol.* 2006; 12:3628–3635. [PubMed: 16773677]
174. Ahmad T, Armuzzi A, Neville M, Bunce M, Ling KL, Welsh KI, et al. The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis. *Tissue Antigens.* 2003; 62:527–535. [PubMed: 14617036]
175. Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. *PLoS Genet.* 2008; 4:e1000024. [PubMed: 18437207]
176. Heward JM, Allababadi A, Daykin J, Carr-Smith J, Daly A, Armitage M, et al. Linkage disequilibrium between the human leukocyte antigen class II region of the major histocompatibility complex and Graves' disease: replication using a population case control and family-based study. *J Clin Endocrinol Metab.* 1998; 83:3394–3397. [PubMed: 9768636]
177. Simmonds MJ, Howson JM, Heward JM, Cordell HJ, Foxall H, Carr-Smith J, et al. Regression mapping of association between the human leukocyte antigen region and Graves disease. *Am J Hum Genet.* 2005; 76:157–163. [PubMed: 15558498]
178. Zeitlin AA, Heward JM, Newby PR, Carr-Smith JD, Franklyn JA, Gough SC, et al. Analysis of HLA class II genes in Hashimoto's thyroiditis reveals differences compared to Graves' disease. *Genes Immun.* 2008; 9:358–363. [PubMed: 18449200]
179. Lincoln MR, Ramagopalan SV, Chao MJ, Herrera BM, Deluca GC, Orton SM, et al. Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. *Proc Natl Acad Sci U S A.* 2009; 106:7542–7547. [PubMed: 19380721]
180. Matsuki K, Grumet FC, Lin X, Gelb M, Guilleminault C, Dement WC, et al. DQ (rather than DR) gene marks susceptibility to narcolepsy. *Lancet.* 1992; 339:1052. [PubMed: 1349071]
181. Juji T, Satake M, Honda Y, Doi Y. HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. *Tissue Antigens.* 1984; 24:316–319. [PubMed: 6597978]
182. Mignot E, Lin X, Arrigoni J, Macaubas C, Olive F, Hallmayer J, et al. DQB1*0602 and DQA1*0102 (DQ1) are better markers than DR2 for narcolepsy in Caucasian and black Americans. *Sleep.* 1994; 17:S60–67. [PubMed: 7701202]
183. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. *Arthritis Rheum.* 1987; 30:1205–1213. [PubMed: 2446635]
184. Graham RR, Ortmann WA, Langefeld CD, Jawaheer D, Selby SA, Rodine PR, et al. Visualizing human leukocyte antigen class II risk haplotypes in human systemic lupus erythematosus. *Am J Hum Genet.* 2002; 71:543–553. [PubMed: 12145745]
185. Tsao BP. Update on human systemic lupus erythematosus genetics. *Curr Opin Rheumatol.* 2004; 16:513–521. [PubMed: 15314487]
186. Kawabata Y, Ikegami H, Kawaguchi Y, Fujisawa T, Shintani M, Ono M, et al. Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes to susceptibility to type 1 diabetes. *Diabetes.* 2002; 51:545–551. [PubMed: 11812768]
187. She JX. Susceptibility to type I diabetes: HLA-DQ and DR revisited. *Immunology today.* 1996; 17:323–329. [PubMed: 8763818]
188. Lambert AP, Gillespie KM, Thomson G, Cordell HJ, Todd JA, Gale EA, et al. Absolute risk of childhood-onset type 1 diabetes defined by human leukocyte antigen class II genotype: a population-based study in the United Kingdom. *J Clin Endocrinol Metab.* 2004; 89:4037–4043. [PubMed: 15292346]
189. Erlich HA, Bugawan TL, Scharf S, Nepom GT, Tait B, Griffith RL. HLA-DQ beta sequence polymorphism and genetic susceptibility to IDDM. *Diabetes.* 1990; 39:96–103. [PubMed: 2210066]
190. Almarri A, Batchelor JR. HLA and hepatitis B infection. *Lancet.* 1994; 344:1194–1195. [PubMed: 7934542]

191. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. *Nat Genet.* 2009; 41:591–595. [PubMed: 19349983]
192. Anderson DC, van Schooten WC, Barry ME, Janson AA, Buchanan TM, de Vries RR. A *Mycobacterium leprae*-specific human T cell epitope cross-reactive with an HLA-DR2 peptide. *Science.* 1988; 242:259–261. [PubMed: 2459778]
193. Vanderborght PR, Pacheco AG, Moraes ME, Antoni G, Romero M, Verville A, et al. HLA-DRB1*04 and DRB1*10 are associated with resistance and susceptibility, respectively, in Brazilian and Vietnamese leprosy patients. *Genes Immun.* 2007; 8:320–324. [PubMed: 17396103]
194. Ravikumar M, Dheenadhayalan V, Rajaram K, Lakshmi SS, Kumaran PP, Paramasivan CN, et al. Associations of HLA-DRB1, DQB1 and DPB1 alleles with pulmonary tuberculosis in south India. *Tuber Lung Dis.* 1999; 79:309–317. [PubMed: 10707259]
195. Singh SP, Mehra NK, Dingley HB, Pande JN, Vaidya MC. Human leukocyte antigen (HLA)-linked control of susceptibility to pulmonary tuberculosis and association with HLA-DR types. *J Infect Dis.* 1983; 148:676–681. [PubMed: 6415179]

Figure 1. Genes and genetic diversity in the MHC class II region

The classical MHC class I, class III and class II regions are shown at chromosome 6p21 together with a higher resolution plot showing the location of genes within the MHC class II region chr6:32,250,000-33,300,000 (hg18 build 36). Structural genomic variation from the Database of Genomic Variants¹⁶⁶ are shown (copy number variants in orange, insertions/deletions dark green) together with location of microsatellites and sequence level variation in terms of single nucleotide polymorphisms and small insertions and deletions (indels) (dbSNP build 129).¹⁶⁷ Images adapted from UCSC Genome Browser.¹⁶⁸

Figure 2. Regulation of MHC class II transcription

Schematic representation of transcriptional regulation for an MHC class II gene. The MHC class II enhanceosome is shown resulting from recruitment of different binding factors including RFX, CREB and NF-Y to the S, X, X2 and Y box sequences located in the proximal promoter region. This recruits the master regulator CIITA which directs transcription.

Figure 3. Major human HLA-DR haplogroups

Five haplogroups are shown denoted *DR1*, *DR8*, *DR51*, *DR52* and *DR53*. These differ by the presence of an additional functional *DRB* gene (*DRB3*, *DRB4* or *DRB5*) (shown in black) and a varying number of *DRB* pseudogenes (*DRB2*, *DRB6*, *DRB7*, *DRB8* or *DRB9*) (shown in grey). The *DRB1* allelic lineages can be resolved to five families which relate to the five main haplogroups: *HLA-DRB1**01 and *10 (*DR1*), *08 (*DR8*), *15 and *16 (*DR51*), *03, *11, *13 and *14 (*DR52*), and *4, *7 and *9 (*DR53*). Gene transcript structure derived from Ensembl but note figure schematic rather than drawn to scale with respect to location.

Figure 4. Sequence conservation and regulatory elements in proximal promoter region of *HLA-DRB1*

(A) Evidence of haplotype specific sequence variation involving regulatory sequences in *HLA-DRB1* involving both X and Y boxes. DR4, DR7 and DR9 (the *DR53* haplogroup) contain the highest variability. Such variants may explain the observed allele specific differential expression at this locus. (B) Dendrogram showing the relationship between the regulatory regions obtained from a pairwise similarity score. In general, regulatory sequence clusters correspond to the different ancestral haplotype groups. The proximal promoter sequence of the DR8 haplotype shows high degrees of similarity to that of the DR52 haplotype. Another cluster of homologous sequences consists of DR4, DR7 and DR9 (the *DR53* haplogroup) and seems to have evolved independently.

Figure 5. A conserved VDRE confers responsiveness to vitamin D to *HLA-DRB1*

Schematic illustrating the role of a proximal VDRE at the *HLA-DRB1* gene which confers vitamin D responsiveness through binding of VDR/RXR.

Table 1

Summary of major MHC class II associations with autoimmune, inflammatory and infectious diseases

<i>Immune and autoimmune</i>			
Disease	Class II association	Comments	Reference
Celiac disease	<i>HLA-DQA*0501-DQB1*0201</i>		169
Crohn's disease	<i>HLA-DRB1*0103</i> , *04, *0701 and <i>HLA-DRB3*0301</i>	The most consistently reproducible finding is <i>HLA-DRB1*0701</i>	170,173
Ulcerative colitis	<i>HLA-DRB1*0103</i> and *1502	<i>HLA-DRB1*0103</i> is the most reproducible association	170,174,175
Graves disease	<i>HLA-DRB1*03-DQB1*02-DQA1*0501</i>	Logistic-regression analysis shows that the association could be explained by either DRB1 or DQA1	176,177
Hashimoto's thyroiditis	<i>HLA-DRB1*04-DQB1*03-DQA1*03</i>		178
Multiple sclerosis	<i>HLA-DRB1*1501-DQB1*0602</i> , <i>HLA-DRB1*0301-DQB1*0201</i> , <i>HLA-DRB1*0405-DQB1*0301</i>	The most consistently reproducible finding is <i>HLA-DRB1*1501</i> in Northern Europeans. Epistasis among <i>HLA-DRB1</i> , <i>HLA-DQA1</i> , and <i>HLA-DQB1</i> loci has been shown to influence MS risk.	94,98,179
Narcolepsy	<i>HLA-DQB1*0602</i>	<i>HLA-DQB1*0601</i> associated with protection	180,182
Rheumatoid arthritis	<i>HLA-DRB1</i> shared epitope susceptibility alleles *0101, *0401, and *0404 in Europeans and *0405 and *0901 in Asians.	<i>HLA-DRB1*04</i> alleles confer high risk and the rest exhibit a more moderate risk	175,183
SLE	<i>HLA-DR3</i> and <i>HLA-DR2</i> haplotypes		184,185
Type 1 diabetes	Europeans: <i>DRB1*0401-DQA1*0301-DQB1*0302</i> and <i>DRB1*0301-DQA1*0501-DQB1*0201</i> Asians: <i>DRB1*0405-DQB1*0401</i> and <i>DRB1*0901-DQB1*0303</i>	Heterozygosity for both European haplotypes confers the greatest risk for T1D	10,186,189
<i>Infectious disease</i>			
Hepatitis B	<i>HLA-DR7</i> , <i>HLA-DPA1*0103-DPB1*0402</i> and <i>HLA-DPA1*0103-DPB1*0401</i>	<i>HLA*DP</i> is associated with chronic hepatitis B in Asians	190,191
Leprosy	<i>HLA-DR2</i> , <i>HLA-DRB1*10</i>		192,193
Tuberculosis	<i>HLA-DR2</i>		194,195